The study provides molecular evidence that different antigenic peptides are recognized by T cells in the mitral valve versus the myocardium in rheumatic heart disease, supporting an antigen-driven immune response rather than a superantigen effect.
No takes yet. Share an insight, caveat, or question.
Does not yet alter rheumatic heart disease management; leaves open dominant epitope identification for antigen-specific therapies.
Guilherme et al. (2000) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: